Ser16

Site Information
RSAIRRAstIEMPQQ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 448114

In vivo Characterization
Methods used to characterize site in vivo:	[32P] bio-synthetic labeling ( 72 ) , immunoprecipitation ( 68 ) , mass spectrometry ( 17 , 23 , 27 , 28 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 ) , mutation of modification site ( 18 , 19 , 29 , 64 , 66 , 68 ) , peptide sequencing ( 72 ) , phospho-antibody ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 12 , 13 , 14 , 15 , 16 , 18 , 19 , 20 , 21 , 22 , 25 , 29 , 40 , 41 , 63 , 64 , 65 , 67 , 68 , 69 , 70 , 71 ) , phosphoamino acid analysis ( 72 ) , phosphopeptide mapping ( 72 ) , western blotting ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 12 , 13 , 14 , 15 , 16 , 18 , 19 , 20 , 21 , 22 , 25 , 29 , 40 , 41 , 63 , 64 , 65 , 67 , 69 )
Relevant cell line - cell type - tissue:	'muscle, smooth' ( 63 ) , 'stem, induced pluripotent' ( 5 ) , 293 (epithelial) ( 16 , 19 ) , cardiac-heart ( 9 , 19 ) , heart ( 2 , 4 , 6 , 7 , 8 , 13 , 18 , 20 , 23 , 25 , 27 , 28 , 32 , 33 , 36 , 37 , 38 , 39 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 58 , 59 , 60 , 61 , 62 , 65 , 67 , 72 ) , heart [PLB (mouse)] ( 70 , 71 ) , heart [RYR2 (mouse), genetic knockin] ( 29 ) , HL-1 (myocyte) [Akt1 (mouse), knockdown, stable lentiviral expression of Akt1 shRNA] ( 17 ) , HL-1 (myocyte) [Akt2 (mouse), knockdown, stable lentiviral expression of Akt2 shRNA] ( 17 ) , HL-1 (myocyte) ( 17 ) , kidney ( 28 ) , liver ( 34 , 35 ) , lung ( 28 ) , myocardium ( 10 ) , myocyte-heart ( 1 , 3 , 5 , 12 , 14 , 15 , 21 , 22 , 41 , 64 , 66 , 68 ) , myocyte-heart [PLB (mouse), genetic knockin] ( 66 ) , myocyte-heart [PLB (mouse), homozygous knockout] ( 66 ) , myocyte-heart [PMCA4 iso2 (human), transgenic] ( 40 ) , myocyte-heart [SERCA2 (mouse), transfection] ( 69 ) , thymus ( 30 , 31 )

In vivo Characterization

Methods used to characterize site in vivo:

[32P] bio-synthetic labeling ( 72 ) , immunoprecipitation ( 68 ) , mass spectrometry ( 17 , 23 , 27 , 28 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 ) , mutation of modification site ( 18 , 19 , 29 , 64 , 66 , 68 ) , peptide sequencing ( 72 ) , phospho-antibody ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 12 , 13 , 14 , 15 , 16 , 18 , 19 , 20 , 21 , 22 , 25 , 29 , 40 , 41 , 63 , 64 , 65 , 67 , 68 , 69 , 70 , 71 ) , phosphoamino acid analysis ( 72 ) , phosphopeptide mapping ( 72 ) , western blotting ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 12 , 13 , 14 , 15 , 16 , 18 , 19 , 20 , 21 , 22 , 25 , 29 , 40 , 41 , 63 , 64 , 65 , 67 , 69 )

Relevant cell line - cell type - tissue:

'muscle, smooth' ( 63 ) , 'stem, induced pluripotent' ( 5 ) , 293 (epithelial) ( 16 , 19 ) , cardiac-heart ( 9 , 19 ) , heart ( 2 , 4 , 6 , 7 , 8 , 13 , 18 , 20 , 23 , 25 , 27 , 28 , 32 , 33 , 36 , 37 , 38 , 39 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 58 , 59 , 60 , 61 , 62 , 65 , 67 , 72 ) , heart [PLB (mouse)] ( 70 , 71 ) , heart [RYR2 (mouse), genetic knockin] ( 29 ) , HL-1 (myocyte) [Akt1 (mouse), knockdown, stable lentiviral expression of Akt1 shRNA] ( 17 ) , HL-1 (myocyte) [Akt2 (mouse), knockdown, stable lentiviral expression of Akt2 shRNA] ( 17 ) , HL-1 (myocyte) ( 17 ) , kidney ( 28 ) , liver ( 34 , 35 ) , lung ( 28 ) , myocardium ( 10 ) , myocyte-heart ( 1 , 3 , 5 , 12 , 14 , 15 , 21 , 22 , 41 , 64 , 66 , 68 ) , myocyte-heart [PLB (mouse), genetic knockin] ( 66 ) , myocyte-heart [PLB (mouse), homozygous knockout] ( 66 ) , myocyte-heart [PMCA4 iso2 (human), transgenic] ( 40 ) , myocyte-heart [SERCA2 (mouse), transfection] ( 69 ) , thymus ( 30 , 31 )

Upstream Regulation
Regulatory protein:	ADRB1 (mouse) ( 23 ) , ANPB (mouse) ( 10 ) , CAMK2D (mouse) ( 67 ) , H2R (mouse) ( 7 ) , PDE3A (mouse) ( 1 ) , plakophilin 2 (mouse) ( 8 ) , PMCA4 iso2 (human) ( 40 ) , PPP5C (human) ( 6 ) , SERCA2 (human) ( 3 ) , SERCA2 (mouse) ( 69 ) , Spinophilin (mouse) ( 19 ) , TNNT2 (human) ( 5 ) , TPM1 (mouse) ( 22 , 26 )
Kinases, in vitro:	CAMK2A (mouse) ( 68 ) , PKACA (mouse) ( 24 , 68 )
Putative upstream phosphatases:	PPP2CA (human) ( 6 )
Treatments:	adriamycin ( 14 ) , amitriptyline ( 7 ) , autocamtide_inhibitory_peptide ( 20 , 65 ) , bisindolylmaleimide ( 41 ) , bite-opening ( 13 ) , cGMP_analog ( 63 ) , CNP ( 1 , 10 ) , cpTOME ( 41 ) , cyclopiazonic_acid ( 63 ) , dobutamine ( 65 ) , electrical_stimulation ( 64 ) , H-89 ( 16 ) , high-fat diet ( 15 ) , histamine ( 2 , 7 ) , hypothermia ( 2 ) , IBMX ( 16 ) , inhibitor-1 ( 25 ) , isoproterenol ( 9 , 15 , 16 , 21 , 40 , 68 , 72 ) , ITI-214 ( 1 ) , KN-93 ( 63 ) , levosimendan ( 4 ) , linagliptin ( 12 ) , NKH_477 ( 16 ) , ODQ ( 63 ) , propranolol ( 4 , 13 ) , rolipram ( 4 ) , SNAP ( 12 ) , SNP ( 1 , 63 ) , TAC ( 10 ) , wheel running test ( 8 )

Downstream Regulation
Effects of modification on PLB:	activity, induced ( 11 , 66 ) , molecular association, regulation ( 11 , 24 ) , protein conformation ( 11 ) , protein degradation ( 16 )
Effects of modification on biological processes:	apoptosis, induced ( 13 )
Induce interaction with:	ATP2A1 (human) ( 11 )
Inhibit interaction with:	PPP1R3A (mouse) ( 24 )

References
1	Bork NI, et al. (2023) Role of Phosphodiesterase 1 in the Regulation of Real-Time cGMP Levels and Contractility in Adult Mouse Cardiomyocytes. Cells 12 38067187 Curated Info
2	Hoffmann RJR, et al. (2023) Temperature alters the inotropic, chronotropic and proarrhythmic effects of histamine in atrial muscle preparations from humans and H-receptor overexpressing mice. Naunyn Schmiedebergs Arch Pharmacol 396, 2137-2150 36951998 Curated Info
3	Gonnot F, et al. (2023) SERCA2 phosphorylation at serine 663 is a key regulator of Ca homeostasis in heart diseases. Nat Commun 14, 3346 37291092 Curated Info
4	Abella LMR, et al. (2023) Levosimendan increases the phosphorylation state of phospholamban in the isolated human atrium. Naunyn Schmiedebergs Arch Pharmacol 396, 669-682 36445386 Curated Info
5	Kondo T, et al. (2022) Human-Induced Pluripotent Stem Cell-Derived Cardiomyocyte Model for Δ160E-Induced Cardiomyopathy. Circ Genom Precis Med 15, e003522 35861968 Curated Info
6	Dörner MF, et al. (2021) Mechanisms of Systolic Cardiac Dysfunction in PP2A, PP5 and PP2AxPP5 Double Transgenic Mice. Int J Mol Sci 22 34502355 Curated Info
7	Neumann J, et al. (2021) Amitriptyline functionally antagonizes cardiac H histamine receptors in transgenic mice and human atria. Naunyn Schmiedebergs Arch Pharmacol 33625558 Curated Info
8	Hammer KP, et al. (2021) Beneficial effect of voluntary physical exercise in Plakophilin2 transgenic mice. PLoS One 16, e0252649 34086773 Curated Info
9	Werhahn SM, et al. (2021) Adaptive versus maladaptive cardiac remodelling in response to sustained β-adrenergic stimulation in a new 'ISO on/off model'. PLoS One 16, e0248933 34138844 Curated Info
10	Michel K, et al. (2020) C-type natriuretic peptide moderates titin-based cardiomyocyte stiffness. JCI Insight 33055420 Curated Info
11	Aguayo-Ortiz R, Espinoza-Fonseca LM (2020) Atomistic Structure and Dynamics of the Ca²⁺-ATPase Bound to Phosphorylated Phospholamban. Int J Mol Sci 33019581 Curated Info
12	Batchu SN, et al. (2020) The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans. Int J Mol Sci 32796688 Curated Info
13	Yagisawa Y, et al. (2020) Effects of occlusal disharmony on cardiac fibrosis, myocyte apoptosis and myocyte oxidative DNA damage in mice. PLoS One 32716920 Curated Info
14	Llach A, et al. (2019) Progression of excitation-contraction coupling defects in doxorubicin cardiotoxicity. J Mol Cell Cardiol 126, 129-139 30500377 Curated Info
15	Fu Q, et al. (2017) High-fat diet induces protein kinase A and G-protein receptor kinase phosphorylation of β2 -adrenergic receptor and impairs cardiac adrenergic reserve in animal hearts. J Physiol 595, 1973-1986 27983752 Curated Info
16	Nakagawa T, Yokoe S, Asahi M (2016) Phospholamban degradation is induced by phosphorylation-mediated ubiquitination and inhibited by interaction with cardiac type Sarco(endo)plasmic reticulum Ca(2+)-ATPase. Biochem Biophys Res Commun 472, 523-30 26966065 Curated Info
17	Reinartz M, Raupach A, Kaisers W, Gödecke A (2014) AKT1 and AKT2 induce distinct phosphorylation patterns in HL-1 cardiac myocytes. J Proteome Res 13, 4232-45 25162660 Curated Info
18	Di Carlo MN, et al. (2014) CaMKII-dependent phosphorylation of cardiac ryanodine receptors regulates cell death in cardiac ischemia/reperfusion injury. J Mol Cell Cardiol 74, 274-83 24949568 Curated Info
19	Chiang DY, et al. (2014) Impaired local regulation of ryanodine receptor type 2 by protein phosphatase 1 promotes atrial fibrillation. Cardiovasc Res 103, 178-87 24812280 Curated Info
20	Chakraborty A, et al. (2014) Inhibition of CaMKII Does Not Attenuate Cardiac Hypertrophy in Mice with Dysfunctional Ryanodine Receptor. PLoS One 9, e104338 25093823 Curated Info
21	Besser J, et al. (2014) MiRNA-1/133a Clusters Regulate Adrenergic Control of Cardiac Repolarization. PLoS One 9, e113449 25415383 Curated Info
22	Schulz EM, et al. (2013) Decreasing Tropomyosin Phosphorylation Rescues Tropomyosin-induced Familial Hypertrophic Cardiomyopathy. J Biol Chem 288, 28925-28935 23960072 Curated Info
23	Lundby A, et al. (2013) In vivo phosphoproteomics analysis reveals the cardiac targets of β-adrenergic receptor signaling. Sci Signal 6, rs11 23737553 Curated Info
24	Vafiadaki E, Arvanitis DA, Sanoudou D, Kranias EG (2013) Identification of a protein phosphatase-1/phospholamban complex that is regulated by cAMP-dependent phosphorylation. PLoS One 8, e80867 24244723 Curated Info
25	Pritchard TJ, et al. (2013) Active inhibitor-1 maintains protein hyper-phosphorylation in aging hearts and halts remodeling in failing hearts. PLoS One 8, e80717 24312496 Curated Info
26	Schulz EM, et al. (2012) Tropomyosin dephosphorylation results in compensated cardiac hypertrophy. J Biol Chem 287, 44478-89 23148217 Curated Info
27	Deng N, et al. (2011) Phosphoproteome analysis reveals regulatory sites in major pathways of cardiac mitochondria. Mol Cell Proteomics 10, M110.000117 20495213 Curated Info
28	Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89 21183079 Curated Info
29	Sarma S, et al. (2010) Genetic inhibition of PKA phosphorylation of RyR2 prevents dystrophic cardiomyopathy. Proc Natl Acad Sci U S A 107, 13165-70 20615971 Curated Info
30	Guo A (2009) CST Curation Set: 8170; Year: 2009; Biosample/Treatment: tissue, thymus/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
31	Guo A (2009) CST Curation Set: 8169; Year: 2009; Biosample/Treatment: tissue, thymus/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
32	Zhou J (2009) CST Curation Set: 7444; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
33	Zhou J (2009) CST Curation Set: 7445; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
34	Zhou J (2009) CST Curation Set: 7426; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST] Curated Info
35	Zhou J (2009) CST Curation Set: 7425; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST] Curated Info
36	Zhou J (2009) CST Curation Set: 7417; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST] Curated Info
37	Zhou J (2009) CST Curation Set: 7418; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST] Curated Info
38	Zhou J (2009) CST Curation Set: 7385; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST] Curated Info
39	Zhou J (2009) CST Curation Set: 7386; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST] Curated Info
40	Mohamed TM, et al. (2009) Specific role of neuronal nitric-oxide synthase when tethered to the plasma membrane calcium pump in regulating the beta-adrenergic signal in the myocardium. J Biol Chem 284, 12091-8 19278978 Curated Info
41	Oestreich EA, et al. (2009) Epac and phospholipase Cepsilon regulate Ca2+ release in the heart by activation of protein kinase Cepsilon and calcium-calmodulin kinase II. J Biol Chem 284, 1514-22 18957419 Curated Info
42	Stokes M (2008) CST Curation Set: 5664; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
43	Stokes M (2008) CST Curation Set: 5665; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
44	Stokes M (2008) CST Curation Set: 5168; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
45	Stokes M (2008) CST Curation Set: 5087; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
46	Stokes M (2008) CST Curation Set: 5088; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
47	Stokes M (2008) CST Curation Set: 5089; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
48	Stokes M (2008) CST Curation Set: 5090; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
49	Stokes M (2008) CST Curation Set: 5091; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
50	Stokes M (2008) CST Curation Set: 5092; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
51	Stokes M (2008) CST Curation Set: 5093; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
52	Stokes M (2008) CST Curation Set: 5094; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
53	Zhou J (2008) CST Curation Set: 4782; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988 Curated Info
54	Rikova K (2008) CST Curation Set: 4776; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KTL(LN)-4/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
55	Rikova K (2008) CST Curation Set: 4772; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KTL-1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
56	Rikova K (2008) CST Curation Set: 4760; Year: 2008; Biosample/Treatment: cell line, Dana Farber-L1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
57	Rikova K (2008) CST Curation Set: 4762; Year: 2008; Biosample/Treatment: cell line, Dana Farber-L2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
58	Possemato A (2008) CST Curation Set: 3820; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
59	Possemato A (2008) CST Curation Set: 3830; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
60	Guo A (2007) CST Curation Set: 3118; Year: 2007; Biosample/Treatment: tissue, heart/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb Cat#: 9634, PTMScan(R) Phospho-PDK1 Docking Motif (F/YS/TF/Y) Immunoaffinity Beads Cat#: 1992 Curated Info
61	Guo A (2007) CST Curation Set: 2923; Year: 2007; Biosample/Treatment: tissue, heart/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CKII Substrate Antibody (polyAb) Cat#: 5808, PTMScan(R) Phospho-CK Substrate Motif (S/TD/EXD/E) Immunoaffinity Beads Cat#: 1994 Curated Info
62	Guo A (2007) CST Curation Set: 2829; Year: 2007; Biosample/Treatment: tissue, heart/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
63	Kim M, Perrino BA (2007) CaM kinase II activation and phospholamban phosphorylation by SNP in murine gastric antrum smooth muscles. Am J Physiol Gastrointest Liver Physiol 292, G1045-54 17185633 Curated Info
64	Zhao W, et al. (2004) Threonine-17 phosphorylation of phospholamban: a key determinant of frequency-dependent increase of cardiac contractility. J Mol Cell Cardiol 37, 607-12 15276030 Curated Info
65	Ji Y, et al. (2003) Targeted inhibition of Ca2+/calmodulin-dependent protein kinase II in cardiac longitudinal sarcoplasmic reticulum results in decreased phospholamban phosphorylation at threonine 17. J Biol Chem 278, 25063-71 12692124 Curated Info
66	Li Y, Kranias EG, Mignery GA, Bers DM (2002) Protein kinase A phosphorylation of the ryanodine receptor does not affect calcium sparks in mouse ventricular myocytes. Circ Res 90, 309-16 11861420 Curated Info
67	Zhang T, et al. (2002) The cardiac-specific nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J Biol Chem 277, 1261-7 11694533 Curated Info
68	Chu G, et al. (2000) A single site (Ser16) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to beta -agonists. J Biol Chem 275, 38938-43 10988285 Curated Info
69	Ji Y, et al. (2000) Disruption of a single copy of the SERCA2 gene results in altered Ca2+ homeostasis and cardiomyocyte function. J Biol Chem 275, 38073-80 10970890 Curated Info
70	Mayer EJ, Huckle W, Johnson RG, McKenna E (2000) Characterization and quantitation of phospholamban and its phosphorylation state using antibodies. Biochem Biophys Res Commun 267, 40-8 10623571 Curated Info
71	Mayer EJ, Savage GM, Johnson RG (1998) A quantitative immunoassay for the measurement of phospholamban levels and phosphorylation states. Measurement of phospholamban levels in transgenic mouse hearts. Ann N Y Acad Sci 853, 284-7 10603960 Curated Info
72	Wegener AD, Simmerman HK, Lindemann JP, Jones LR (1989) Phospholamban phosphorylation in intact ventricles. Phosphorylation of serine 16 and threonine 17 in response to beta-adrenergic stimulation. J Biol Chem 264, 11468-74 2544595 Curated Info